Home     Archives     Search     Authors     About Us     Subscribe     Contact Us  

Search For:
Search In:

The i2P magazine is distributed by email on a monthly basis. Subscription is free and you can unsubscribe at any time.
Subscribe Here
Unsubscribe Here

If you have any concerns for your privacy, please read our Privacy Policy

- Issue 81: April 2009
- Issue 80: March 2009
- Issue 79: February 2009
- Issue 78: December 2008
- Issue 77: November 2008
- Issue 76: October 2008
- Issue 75: September 2008
- Issue 74: August 2008
- Issue 73: July 2008
- Issue 72: June 2008

More Archives
We are in the process of moving all of our articles to the new site.

In the meantime you can find them on the old i2P site.

Around the Traps

By a Staff Writer
News Items, Background Information and Items of Interest

Issue 78: December 2008
Page: 1 of 1 Author's Profile | Send to a Friend | Printer Version

Organisations with pharmacy connections are invited to share their news, product releases or opinions in this column.

This Month:

  * HIP Newsletter

 * NEW ANALYSIS suggests THAT improveMENTS IN kidney function in patients treated WITH LIPITOR STRONGLY CORRELATE WITH A reduced risk of major cardiovascular events


HIP logo
This Month
Chemconsult® online flags some worrying prescription error rates
HIP Conference addressed by Olympic gold medallist
More than a satisfied customer
Movember at HIP
New People and Places
Join Our List
Join Our Mailing List
  November 2008

Chemconsult® online flags some worrying prescription error rates

Chemconsult posterDesensitised data from 2204 Chemconsult® consultations across the Health Information Pharmacy group's pharmacies to 30th October 2008 have flagged some alarming error... Click to continue

HIP Conference addressed by Olympic gold medallist

Delegates at the recent Health Information Pharmacy group conference in Melbourne heard Steven Bradbury, men's short-track... Click to continue

More than a satisfied customer - Kaye's story

As well as Olympic gold medallist Steven Bradbury, delegates at the HIP group conference in Melbourne also heard from Kaye Cheng... Click to continue

Movember at HIP

Movember at MoloolabaWould you trust these men? (statistically speaking the answer is a resounding 'yes' ... Click to continue

New People and Places

An update on new people and new places in the HIP group... Click to continue
About HIP
Health Information Pharmacy is an award-winning Australian pharmacy group - independent of wholesaler groups and developed by pharmacists and business coaches.  It is based around a model developed by the founder, Ken Lee, in his Castle Hill NSW pharmacy - which won NSW/ACT Pharmacy of the Year in 2003. More...


NEW ANALYSIS suggests THAT improveMENTS IN kidney function in patients treated WITH LIPITOR STRONGLY CORRELATE WITH A reduced risk of major cardiovascular events


Improvements in kidney function in patients treated with LIPITOR*® (atorvastatin calcium) were shown to strongly correlate with a reduced risk of major cardiovascular events in patients with pre-existing cardiovascular disease, according to a post hoc sub-analysis of the five-year Treating to New Targets (TNT) study presented on 12 November, 2008 at the Annual Scientific Sessions of the American Heart Association.

“This is important for patients, since studies have shown that people with high cholesterol have a more rapid decrease in kidney function over time and that chronic kidney disease is more frequent in patients with cardiovascular disease” said Dr James Shepherd, clinical academic consultant, department of pathological biochemistry, University of Glasgow Medical School, and lead investigator of the analysis. 

In this new post hoc analysis, kidney function was assessed using estimated glomerular filtration rate (eGFR), as recommended by the American National Kidney Foundation.  Increases in eGFR indicate improved kidney function.

LIPITOR*® has previously been shown to provide dose-dependent increases in eGFR in heart disease patients.  Findings from this new analysis showed that in patients with heart disease treated with LIPITOR*®, for each 1 mL/min/1.73 m2 increase in eGFR there was a 2.7 percent relative reduction in risk of major cardiovascular events.  Similar risk reductions per 1 mL/min/1.73 m2 increase in eGFR were observed for secondary endpoints such as major coronary events, nonfatal heart attack and fatal or nonfatal stroke. 

Throughout the TNT study, both doses of Lipitor (10 and 80 mg) were generally well-tolerated.

About the TNT Study

The TNT study was an investigator-led trial coordinated by an independent steering committee and funded by Pfizer.  The study enrolled 10,001 men and women with clinically evident coronary heart disease aged 35 years to 75 years in 14 countries and followed them for an average of five years. Patients were randomly assigned to double-blind therapy with 10 or 80 mg/day LIPITOR*® (atorvastatin). Primary study results were published in The New England Journal of Medicine in 2005.

The primary endpoint of the original TNT study was the occurrence of a first major cardiovascular event, defined as death from heart disease, non-fatal heart attacks, resuscitated cardiac arrest, or fatal or non-fatal strokes.

Important Information for Australian Doctors

LIPITOR*® (atorvastatin) is indicated as an adjunct to diet for the treatment of patients with hypercholesterolaemia. Also indicated in hypertensive patients with multiple risk factors for CHD to reduce the risk of non-fatal myocardial infarction and non-fatal stroke. 

Before prescribing please review full Product Information available from Pfizer Australia Pty Ltd (ABN 50 008 422 348)
38-42 Wharf Road, WEST RYDE NSW 2114.

PBS Information: Restricted benefit. For use in patients that meet the

criteria set out in the General Statement for Lipid-Lowering Drugs.

Minimum Product Information: LIPITOR*® (atorvastatin) 10mg, 20mg, 40mg and 80mg Tablets. Contraindications: Hypersensitivity to the active substance or to any of the excipients, active liver disease or unexplained persistent elevations of serum transaminases; pregnancy and lactation. Women of child-bearing potential. Precautions: Liver Dysfunction: liver tests should beperformed before initiation of treatment and periodically thereafter; patients who consume substantial quantities of alcohol and/or have a history of liver disease; myopathy(monitor cpk); risk factors predisposing to development of renal failure secondary to rhabdomyolysis; †history of haemorrhagic stroke or lacunar infarct; use of concomitant medications that may reduce activity/levels of steroid hormones (ketoconazole, spironolactone and cimetidine); interactions with other medicines: inhibitors of cytochrome P450 3A4, other HMG-CoA reductase inhibitors, antacid, colestipol, †OATP1B1 transporter inhibitors, e.g. cyclosporin, erythromycin/ clarithromycin, protease inhibitors, †diltiazem hydrochloride, †itraconazole, †grapefruit juice, digoxin, oral contraceptives. Adverse Reactions: For complete list see full Product Information. Headache, asthenia, abdominal pain, dyspepsia, nausea, flatulence, constipation, diarrhoea, insomnia, myalgia. Dosage: 10–80mg/day as a single daily dose. Presentation: 10mg, 20mg,

40mg and 80mg Tablets in foil blister packs of 30. Based on full Product Information approved on 11 July 2008.

†Please note changes to Product Information.

LIPITOR*® Reg Trademark Pfizer Inc. Pfizer Medical Affairs: 1800 675 229. H&T PZR0012.

For additional product information, visit www.Pfizer.com.au

Back to Top | Back to Home
Copyright © Computachem Services, All Rights Reserved. Published by Computachem Services, PO Box 297 Alstonville 2477 NSW Australia